Advertisement

PharmacoEconomics

, Volume 37, Issue 2, pp 169–200 | Cite as

Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review

  • Edward T. Chiyaka
  • Van T. Nghiem
  • Lu Zhang
  • Abhishek Deshpande
  • Patricia Dolan Mullen
  • Phuc LeEmail author
Systematic Review

Abstract

Background

Herpes zoster (HZ) is one of the most common diseases among adults. Its reactivation is characterized by a severe and painful complication. In addition to the existing herpes zoster vaccine (ZVL), the FDA approved a new adjuvanted subunit zoster vaccine (RZV) in 2017 for use in adults aged 50 years and older. Several studies have assessed the cost-effectiveness of ZVL, many of which were conducted before the long-term vaccine  efficacy data was available in 2014.

Objective

Our objectives were to (i) summarize and compare the cost-effectiveness analyses (CEAs) of ZVL conducted before and after 2014, (ii) summarize the CEAs of RZV, and (iii) critically assess the cost-effectiveness models and identify key parameters to consider for future CEAs of RZV.

Methods

We searched PubMed and two other databases from inception to March 2018 for original cost-effectiveness, cost-utility, or cost-benefit analyses of HZ vaccines. Three investigators independently reviewed and assessed full-text articles after screening the titles and abstracts to determine eligibility. For all included studies, we assessed study quality using the Drummond and Jefferson's checklist and extracted study characteristics, model structure, vaccine characteristics, incidence of HZ and complications, incremental cost-effectiveness ratio, and sensitivity analyses. We summarized data by type of vaccine, year of publication, and funding sources.

Results

Twenty-seven studies met eligibility criteria. All studies were from high-income countries and were of moderate-to-high or high quality. Twenty studies repeatedly used four cost-effectiveness models. The assumption on long-term efficacy of ZVL was not based on clinical trial data in > 50% of studies. Fifteen out of 25 studies concluded that ZVL was cost-effective compared with no vaccine at a vaccine price ranging between US$93 and US$236 per dose (2018 US$), 40% of which were published after 2014. All industry-funded studies favored the use of ZVL. The single study assessing RZV found it to be more effective and less costly than ZVL, and cost-effective compared with no vaccination. More studies conducted after 2014 included various efficacy endpoints for ZVL, adverse reactions, and productivity loss compared with those conducted before 2014.

Conclusions

A majority of studies of ZVL found it to be cost-effective compared with no vaccine using the authors’ chosen willingness-to-pay thresholds. RZV was dominant in the single study comparing the two vaccines, but the finding needs to be confirmed with further studies in different settings. Future studies should assume vaccine efficacy in line with clinical data, account for more efficacy endpoints for ZVL, and include other HZ long-term complications, vaccine adverse reactions, and productivity loss.

Notes

Author Contributions

AD conducted the literature search. ETC, VTN, and LZ independently reviewed papers, extracted and analyzed data. Disagreement was resolved by discussing with PL. All authors contributed to the interpretation of results and report writing. PL acts as the guarantor. All authors approved the final version of the manuscript as submitted.

Compliance with Ethical Standards

Funding

No funding was received for this study or manuscript.

Conflict of interest

Abhishek Deshpande is on the Speaker Bureau (non-product) for Merck. Other authors (Edward T. Chiyaka, Van T. Nghiem, Lu Zhang, Patricia D. Mullen, and Phuc Le) declare that they have no conflict of interest.

Supplementary material

40273_2018_735_MOESM1_ESM.docx (56 kb)
Supplementary material 1 (DOCX 55 kb)

References

  1. 1.
    Cohen JI. Herpes zoster. N Engl J Med. 2013;369(3):255–63.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Kawai K, Yawn BP, Wollan P, Harpaz R. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63(2):221–6.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356–63.CrossRefGoogle Scholar
  6. 6.
    Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15(1):502.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. In: Mayo clinic proceedings. Elsevier; 2009. p. 787–94.Google Scholar
  8. 8.
    Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.Google Scholar
  9. 9.
    Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21–6.CrossRefGoogle Scholar
  10. 10.
    Centers for Disease C, Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60(44):1528.Google Scholar
  11. 11.
    Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA. 2006;296(2):157–8.CrossRefGoogle Scholar
  12. 12.
    Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2014;60(6):900–9.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Schmader K, Oxman M, Levin M, Johnson G, Zhang J, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep Recomm Rep. 2008;57(5):1–30.Google Scholar
  15. 15.
    Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. Am J Transplant. 2018;18(3):756–62.CrossRefGoogle Scholar
  16. 16.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.CrossRefGoogle Scholar
  17. 17.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefGoogle Scholar
  18. 18.
    Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. PharmacoEconomics. 2013;31(2):125–36.CrossRefGoogle Scholar
  19. 19.
    Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014;32(15):1645–53.CrossRefGoogle Scholar
  20. 20.
    Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;5(15):533.CrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention. Adult vaccine price list. 2018. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed 28 Sept 2018.
  22. 22.
    Bilcke J, Verelst F, Beutels P. Sponsorship bias in base-case values and uncertainty bounds of health economic evaluations? A systematic review of herpes zoster vaccination. Med Decis Mak. 2018;38(6):730–45.CrossRefGoogle Scholar
  23. 23.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64.Google Scholar
  24. 24.
    Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (Clinical research ed). 1996;313(7052):275–83.Google Scholar
  26. 26.
    Le P, Nghiem VT, Mullen PD, Deshpande A. Cost-effectiveness of competing treatment strategies for clostridium difficile infection: a systematic review. Infect Control Hosp Epidemiol. 2018;39(4):412–24.CrossRefGoogle Scholar
  27. 27.
    Statistics; BoL. CPI Inflation Calculator. Available from: https://www.bls.gov/data/inflation_calculator.htm. Accessed 20 Apr 2018.
  28. 28.
    Organisation for Economic Co-operation Development. Consumer Price Indices. Available from: http://stats.oecd.org/index.aspx?datasetcode=mei_prices. Accessed 15 Apr 2018.
  29. 29.
    The World Bank. World Bank Country and Lending Groups. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519. Accessed 2 Oct 2018.
  30. 30.
    Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccines Immunother. 2015;11(4):884–96.CrossRefGoogle Scholar
  31. 31.
    Le P, Rothberg MB. Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis. J Gen Intern Med. 2017;32(2):159–67.CrossRefGoogle Scholar
  32. 32.
    Le P, Rothberg MB. Cost effectiveness of a shingles vaccine booster for currently vaccinated adults in the US. Am J Prev Med. 2017;53(6):829–36.CrossRefGoogle Scholar
  33. 33.
    Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248–58.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. J Med Econ. 2016;19(6):576–86.Google Scholar
  35. 35.
    Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8(1):7.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Pan J, Hsu T-Y, Johnson KD, Xu R, Acosta CJ, Kawai K. Cost-effectiveness analysis of herpes zoster vaccine in adults above 50 in Singapore. Dermatol Sin. 2017;35(4):177–81.CrossRefGoogle Scholar
  37. 37.
    Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;26(13):359.CrossRefGoogle Scholar
  38. 38.
    Annemans L, Bresse X, Gobbo C, Papageorgiou MA. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.Google Scholar
  39. 39.
    Bilde L, Nielsen TT, Ronholt F, Kruse M. The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes. Nordic J Health Econ. 2016;5(2):1–21.CrossRefGoogle Scholar
  40. 40.
    Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: a health economic evaluation for Switzerland. Hum Vaccines Immunother. 2017;13(7):1495–504.CrossRefGoogle Scholar
  41. 41.
    Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost–effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):393–406.CrossRefGoogle Scholar
  42. 42.
    Coretti S, Codella P, Romano F, Ruggeri M, Cicchetti A. Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons. Int J Technol Assess Health Care. 2016;32(4):233–40.CrossRefGoogle Scholar
  43. 43.
    Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489–97.CrossRefGoogle Scholar
  45. 45.
    Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280–8.CrossRefGoogle Scholar
  46. 46.
    Edmunds W, Brisson M, Rose J. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.CrossRefGoogle Scholar
  47. 47.
    Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326–37.CrossRefGoogle Scholar
  48. 48.
    Belchior E, Lévy-Bruhl D, Le Strat Y, Herida M. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people. Hum Vaccines Immunother. 2016;12(9):2378–82.CrossRefGoogle Scholar
  49. 49.
    Van Hoek A, Gay N, Melegaro A, Opstelten W, Edmunds W. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.CrossRefGoogle Scholar
  50. 50.
    van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10(1):237.CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991–1004.CrossRefGoogle Scholar
  52. 52.
    Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.CrossRefGoogle Scholar
  53. 53.
    de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.CrossRefGoogle Scholar
  54. 54.
    Hoshi S-L, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35(24):3264–71.Google Scholar
  55. 55.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccines. 2008;4(3):238–45.CrossRefGoogle Scholar
  56. 56.
    Oxman M, Levin M, Johnson G, Schmader K, Straus S, Gelb L, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefGoogle Scholar
  57. 57.
    Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMedCentralGoogle Scholar
  58. 58.
    Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007;45(11):1527–9.CrossRefGoogle Scholar
  59. 59.
    Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317–25.CrossRefGoogle Scholar
  60. 60.
    Li X, Zhang JH, Betts RF, Morrison VA, Xu R, Itzler RF, et al. Modeling the durability of ZOSTAVAX(R) vaccine efficacy in people ≥ 60 years of age. Vaccine. 2015;33(12):1499–505.CrossRefGoogle Scholar
  61. 61.
    Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–53.CrossRefGoogle Scholar
  62. 62.
    Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, et al. Bias in published cost effectiveness studies: systematic review. BMJ (Clinical research ed). 2006;332(7543):699–703.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Edward T. Chiyaka
    • 1
  • Van T. Nghiem
    • 2
  • Lu Zhang
    • 3
  • Abhishek Deshpande
    • 4
  • Patricia Dolan Mullen
    • 5
  • Phuc Le
    • 4
    Email author
  1. 1.College of Public HealthKent State UniversityKentUSA
  2. 2.SWOG Statistical Center, Fred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Department of Management, Policy and Community HealthThe University of Texas School of Public HealthHoustonUSA
  4. 4.Center for Value-Based Care ResearchMedicine Institute, Cleveland ClinicClevelandUSA
  5. 5.Department of Health Promotion and Behavioral Sciences, Center for Health Promotion and Prevention ResearchThe University of Texas School of Public HealthHoustonUSA

Personalised recommendations